Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06754-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Tao Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Cha…. Hauptthemen laut MEDLINE: Receptors, Neurotensin, Copper Radioisotopes, Chelating Agents, Radiopharmaceuticals. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina , 27599, USA. zhangtaocjh@njmu.edu.cn.
- Department of Radiopharmaceuticals, Nuclear Medicine Clinical Transformation Center, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China. zhangtaocjh@njmu.edu.cn.
- Department of Nuclear Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China. zhangtaocjh@njmu.edu.cn.
- Department of Radiology, Biomedical Research Imaging Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina , 27599, USA.
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, Raleigh, NC, North Carolina State University, NC 27599, USA.
- Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
ORCID-Profile: Tao Zhang, Xinrui Ma, Muyun Xu, Xuedan Wu, Zhanhong Wu, Jin Xie, Zibo Li
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Zhang, T., Ma, X., Xu, M., Cai, J., Cai, J., Cao, Y., Zhang, Z., Ji, X., He, J., Cabrera, G. O. F., Wu, X., Zhao, W., Wu, Z., Xie, J., & Li, Z. (2024). Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06754-2
Vancouver
Zhang T, Ma X, Xu M, Cai J, Cai J, Cao Y, et al. Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06754-2
BibTeX
@article{Zhang2024,
author = {Zhang, Tao and Ma, Xinrui and Xu, Muyun and Cai, Jinghua and Cai, Jianhua and Cao, Yanguang and Zhang, Zhihao and Ji, Xin and He, Jian and Cabrera, German Oscar Fonseca and Wu, Xuedan and Zhao, Weiling and Wu, Zhanhong and Xie, Jin and Li, Zibo},
title = {Chelator boosted tumor-retention and pharmacokinetic properties: development of 64Cu labeled radiopharmaceuticals targeting neurotensin receptor},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06754-2}
}
EUVIMED